Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of “Hold” from Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been assigned an average recommendation of “Hold” from the nineteen analysts that are covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $24.07.

A number of brokerages have recently issued reports on SRPT. Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Thursday, July 9th. Wall Street Zen lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research upgraded Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Benchmark restated a “sell” rating on shares of Sarepta Therapeutics in a research report on Wednesday, September 9th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 28th.

Sarepta Therapeutics Trading Down 3.0%

SRPT stock opened at $18.39 on Friday. The company has a market capitalization of $1.94 billion, a PE ratio of -6.34, a price-to-earnings-growth ratio of 0.30 and a beta of 0.27. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. Sarepta Therapeutics has a one year low of $14.68 and a one year high of $25.32. The company’s 50 day moving average price is $18.76 and its two-hundred day moving average price is $18.77.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.22 by $0.42. The company had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The firm’s quarterly revenue was down 34.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.02 EPS. As a group, analysts predict that Sarepta Therapeutics will post 3.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Tidal Investments LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter valued at $183,000. Baird Financial Group Inc. boosted its holdings in shares of Sarepta Therapeutics by 7.6% during the second quarter. Baird Financial Group Inc. now owns 12,805 shares of the biotechnology company’s stock worth $230,000 after purchasing an additional 901 shares during the period. Nykredit A S bought a new stake in shares of Sarepta Therapeutics in the second quarter worth about $43,000. Corient Private Wealth LP increased its holdings in Sarepta Therapeutics by 273.4% during the 2nd quarter. Corient Private Wealth LP now owns 36,712 shares of the biotechnology company’s stock valued at $660,000 after purchasing an additional 26,880 shares during the period. Finally, Amundi bought a new position in Sarepta Therapeutics during the 2nd quarter valued at approximately $350,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. Its research platforms include RNA-based technologies, gene therapy and gene-editing approaches designed to address the underlying causes of genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for eligible patients with specific genetic mutations, as well as Elevidys, a gene therapy developed to treat certain patients with DMD.